These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30811629)

  • 61. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
    [TBL] [Abstract][Full Text] [Related]  

  • 62. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
    Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
    J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 66. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cell kinetics and growth of squamous cell carcinomas in man.
    Bresciani F; Paoluzi R; Benassi M; Nervi C; Casale C; Ziparo E
    Cancer Res; 1974 Sep; 34(9):2405-15. PubMed ID: 4843539
    [No Abstract]   [Full Text] [Related]  

  • 69. Management of partial and non-responding cutaneous squamous cell carcinoma.
    Jansen P; Lodde GC; Griewank KG; Hadaschik E; Roesch A; Ugurel S; Zimmer L; Livingstone E; Schadendorf D
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():29-34. PubMed ID: 34855242
    [TBL] [Abstract][Full Text] [Related]  

  • 70. METTL3-mediated HPV vaccine enhances the effect of anti PD-1 immunotherapy to alleviate the development of cutaneous squamous cell carcinoma.
    Zhang Y; Wang Y; Guo S; Cui H
    An Bras Dermatol; 2024; 99(2):210-222. PubMed ID: 38030537
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
    Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
    J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
    Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
    Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
    Cavalieri S; Perrone F; Milione M; Bianco A; Alfieri S; Locati LD; Bergamini C; Resteghini C; Galbiati D; Platini F; Licitra L; Bossi P
    Oncology; 2019; 97(2):112-118. PubMed ID: 31112973
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma.
    Shalhout SZ; Park JC; Emerick KS; Sullivan RJ; Kaufman HL; Miller DM
    J Am Acad Dermatol; 2021 Oct; 85(4):1038-1040. PubMed ID: 33476726
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
    Corbett M; Tohani S; Ramli R; O'Duffy F
    JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
    Hanania HL; Lewis DJ
    J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
    Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
    Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.
    Ma WL; Chou CH; Chen JP; Kuo SH
    Dermatol Ther; 2020 Nov; 33(6):e14035. PubMed ID: 32683791
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
    Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
    J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.